Src

Src family kinase (SFK) is a family of non-receptor tyrosine kinases including nine members: Src, Yes, Fyn, and Fgr, forming the SrcA subfamily, Lck, Hck, Blk, and Lyn in the SrcB subfamily, and Frk in its own subfamily. In immune cells, Src-family kinases (SFKs) have been implicated as critical regulators of a large number of intracellular signaling pathways. Src-family kinases (SFKs) occupy a proximal position in numerous signaling transduction cascades including those emanating from the T and B cell antigen receptors, Fc receptors, growth factor receptors, cytokine receptors, and integrins. In addition to these positive regulatory roles, Src-family kinases (SFKs) can also function as negative regulators of cellular signaling by phosphorylating immunoreceptor tyrosine-based inhibitory motifs (ITIMs) on inhibitory receptors, resulting in recruitment and activation of inhibitory molecules such as the phosphatases SHP-1 and SH2 containing 5′ inositol phosphatase (SHIP-1).

Src Inhibitors & Activators

1-Naphthyl PP1
(1-NA-PP 1)

Cat. No.: HY-13941



1-Naphthyl PP1 (1-NA-PP 1) is a selective inhibitor of **src** family kinases. 1-Naphthyl PP1 inhibits v-Src and c-Fyn, c-Abl, CDK2 and CAMK II with IC_{50}s of 1.0, 0.6, 0.6, 18 and 22 μM, respectively.

Purity: 98.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

1-Naphthyl PP1 hydrochloride
(1-NA-PP 1 hydrochloride)

Cat. No.: HY-13941B



1-Naphthyl PP1 hydrochloride (1-NA-PP 1 hydrochloride) is a selective inhibitor of **src** family kinases. 1-Naphthyl PP1 hydrochloride inhibits v-Src and c-Fyn, c-Abl, CDK2 and CAMK II with **IC_{50}**s of 1.0, 0.6, 0.6, 18 and 22 μM, respectively.

Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

1-NM-PP1
(PP1 Analog II)

Cat. No.: HY-13942



1-NM-PP1, a cell-permeable PP1 analog, is a potent **Src family kinases** inhibitor with **IC_{50}**s of 4.3 nM and 3.2 nM for v-Src-as1 and c-Fyn-as1, respectively.

Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

7-Hydroxy-4-chromone
(7-Hydroxychromone)

Cat. No.: HY-N6596



7-Hydroxychromone is a **Src kinase** inhibitor with an **IC_{50}** of <300 μM.

Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

A 419259
(RK-20449)

Cat. No.: HY-15764



A 419259 is a broad-spectrum pyrrolo-pyrimidine inhibitor, designed to enhance selectivity towards the Src family with **IC_{50}** of 9 nM, <3 nM and <3 nM for **Src**, **Lck** and **Lyn**, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

A 419259 trihydrochloride
(RK 20449 trihydrochloride)

Cat. No.: HY-15764A



A 419259 trihydrochloride is a **Src family kinases** inhibitor with **IC_{50}**s of 9 nM, 3 nM and 3 nM for **Src**, **Lck** and **Lyn**, respectively.

Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

A-770041

Cat. No.: HY-11011



A-770041 is selective and orally active Src-family Lck inhibitor; A-770041 is a 147 nM inhibitor of Lck (1 mM ATP) and is 300-fold selective against Fyn, the other Src family kinase involved in T-cell signaling.

Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH

Cat. No.: HY-P1200



Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH (compound 1) is a high-affinity pentapeptide to bind to the src SH2 domain (**IC_{50}**≈1 μM).
Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH is an inhibitor for **src SH3-SH2**:phosphoprotein interactions.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA

Cat. No.: HY-P1200A



Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA (compound 1) is a high-affinity pentapeptide to bind to the src SH2 domain (**IC_{50}**≈1 μM).
Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA is an inhibitor for **src SH3-SH2**:phosphoprotein interactions.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AD80

Cat. No.: HY-101963



AD80, a multikinase inhibitor, inhibits **RET**, **RAF**,**SRC**and **S6K**, with greatly reduced mTOR activity.

Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

AMG-47a

Cat. No.: HY-18303

AMG-47a is a potent and orally active **lymphocyte-specific protein tyrosine kinase (Lck)** inhibitor, with an IC_{50} of 0.2 nM. AMG-47a also inhibits **VEGF2**, **p38α**, **Jak3** and **MLR** and **IL-2** with IC_{50}s of 1 nM, 3 nM, 72 nM, 30 nM and 21 nM, respectively.



Purity: 98.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Antiallergic agent-1

Cat. No.: HY-115723

Antiallergic agent-1, a **Src-family kinase** inhibitor, may serve as a new valuable lead compound for future antiallergic drug discovery.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZD0424

Cat. No.: HY-112314

AZD0424 is an orally active, and dual selective **Src/Abl** kinase inhibitor with potential antineoplastic activity. AZD0424 induces **apoptosis** and cell cycle arrest in lymphoma cells.



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

AZM475271

(M475271)

Cat. No.: HY-13561

AZM475271 is a potent and selective Src kinase inhibitor with IC50 of 5 nM; no inhibitory activity on Flt3, KDR, Tie-2.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Bafetinib

(INNO-406; NS-187)

Cat. No.: HY-50868

Bafetinib is a potent and orally active **Lyn/Bcr-Abl** tyrosine kinase inhibitor. Bafetinib augments the activities of several proapoptotic Bcl-2 homology (BH)3-only proteins (Bim, Bad, Bmf and Bik) and induces apoptosis in Ph^+ leukemia cells via Bcl-2 family-regulated intrinsic apoptosis pathway.



Purity: 99.76%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Bosutinib

(SKI-606)

Cat. No.: HY-10158

Bosutinib is a dual **Src/Abl** inhibitor with IC_{50}s of 1.2 nM and 1 nM, respectively.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Bosutinib D8

(SKI-606 D8)

Cat. No.: HY-10158S

Bosutinib D8 (SKI-606 D8) is a deuterium labeled Bosutinib. Bosutinib is a dual **Src/Abl** inhibitor with IC_{50}s of 1.2 nM and 1 nM, respectively.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg

Caffeic acid-pYEEIE

Cat. No.: HY-P1377

Caffeic acid-pYEEIE, a non-phosphopeptide inhibitor, exhibits potent binding affinity for the GST-Lck-SH2 domain.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Caffeic acid-pYEEIE TFA

Cat. No.: HY-P1377A

Caffeic acid-pYEEIE TFA, a non-phosphopeptide inhibitor, exhibits potent binding affinity for the GST-Lck-SH2 domain.



Purity: 98.21%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

CGP77675

Cat. No.: HY-W062835

CGP77675 is an orally active and potent inhibitor of **Src** family kinases.



Purity: 98.85%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

CGP77675 hydrate

Cat. No.: HY-W062835A

CGP77675 hydrate is an orally active and potent inhibitor of **Src** family kinases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CH6953755

Cat. No.: HY-135299

CH6953755 is a potent, orally active and selective **YES1** kinase (a member of the SRC family) inhibitor with an IC_{50} of 1.8 nM. CH6953755 inhibits YES1 kinase, leading to antitumor activity against YES1 Gene -amplified cancers in vitro and in vivo.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

CSF1R-IN-2

Cat. No.: HY-111787

CSF1R-IN-2 (compound 5) is an oral-active inhibitor of **SRC**, **MET** and **c-FMS**, with IC_{50} values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Damnacanthal

Cat. No.: HY-108485

Damnacanthal is an anthraquinone isolated from the root of Morinda citrifolia. Damnacanthal is a highly potent, selective inhibitor of **$p56^{lck}$ tyrosine kinase** activity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

Damnacanthal-d3

Cat. No.: HY-108485S

Damnacanthal-d3 is the deuterium labeled Damnacanthal. Damnacanthal is an anthraquinone isolated from the root of Morinda citrifolia. Damnacanthal is a highly potent, selective inhibitor of **$p56^{lck}$ tyrosine kinase** activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dasatinib

(BMS-354825)

Cat. No.: HY-10181

Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual **Src/Bcr-Abl** inhibitor with potent antitumor activity. The K_is are 16 pM and 30 pM for Src and Bcr-Abl, respectively.



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Dasatinib hydrochloride

(BMS-354825 hydrochloride)

Cat. No.: HY-10181A

Dasatinib (BMS-354825) hydrochloride is a highly potent, ATP competitive, orally active dual **Src/Bcr-Abl** inhibitor with potent antitumor activity. The K_is are 16 pM and 30 pM for Src and Bcr-Abl, respectively.



Purity: 98.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Dasatinib monohydrate

(BMS-354825 monohydrate)

Cat. No.: HY-10181B

Dasatinib (BMS-354825) monohydrate is a highly potent, ATP competitive, orally active dual **Src/Bcr-Abl** inhibitor with potent antitumor activity. The K_is are 16 pM and 30 pM for Src and Bcr-Abl, respectively.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Dasatinib-d8

(BMS-354825-d8)

Cat. No.: HY-10181S

Dasatinib D8 is a deuterium labeled Dasatinib. Dasatinib is a dual Bcr-Abl and Src family tyrosine kinase inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DC-Srci-6649

Cat. No.: HY-139890

DC-Srci-6649 is a **c-Src** kinase inhibitor that inhibits the phosphorylation and locks c-Src in the inactive state.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DGY-06-116

Cat. No.: HY-136605

DGY-06-116 is an irreversible covalent, selective **Src** inhibitor with an **IC_{50}** of 3nM. DGY-06-116 inhibits FGFR1 with an IC_{50} of 8340 nM.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

eCF506

Cat. No.: HY-112096

eCF506 is a highly potent and orally bioavailable inhibitor of the non-receptor tyrosine kinase **Src** with an **IC_{50}** of less than 0.5 nM.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ENMD-2076

Cat. No.: HY-10987A

ENMD-2076 is a multi-targeted kinase inhibitor with **IC_{50}**s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for **Aurora A**, **Flt3**, **KDR/VEGFR2**, **Flt4/VEGFR3**, **FGFR1**, **FGFR2**, **Src**, **PDGFRα**, respectively.



Purity: 99.12%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ENMD-2076 Tartrate

Cat. No.: HY-10987

ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with **IC_{50}**s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for **Aurora A**, **Flt3**, **KDR/VEGFR2**, **Flt4/VEGFR3**, **FGFR1**, **FGFR2**, **Src**, **PDGFRα**, respectively.



Purity: 98.87%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg

EPQpYEEIPIYL

Cat. No.: HY-P3279

EPQpYEEIPIYL, a phosphopeptide, is a Src homology 2 (SH2) domain ligand. EPQpYEEIPIYL activates Src family members (e.g. Lck, Hck, Fyn) by binding to SH2 domains.



Purity: 98.56%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Fenlean

Cat. No.: HY-123506

Fenlean, a natural squamosamide derivative, is a **Src tyrosine kinase** inhibitor. Fenlean can inhibit over-activated microglia and protect dopaminergic neurons. Fenlean can attenuate neuroinflammation in Parkinson's disease models.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hck-IN-1

Cat. No.: HY-125028

Hck-IN-1 (compound B9), a diphenylpyrazolo compound, is a selective **Nef-dependent Hck** inhibitor with **IC_{50}**s of 2.8 μM, >20 μM for Nef:Hck complex and Hck, respectively.



Purity: 98.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

HG-7-85-01

Cat. No.: HY-15814

HG-7-85-01 is a type II ATP competitive inhibitor of wild-type and gatekeeper mutations forms of **Bcr-Abl**, **PDGFRα**, **Kit**, and **Src kinases**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

iHCK-37

(ASN05260065)

Cat. No.: HY-139147

iHCK-37 (ASN05260065) is a potent and specific **Hck** inhibitor with a **K_i** value of 0.22 μM. iHCK-37 blocks HIV-1 viral replication with an **EC_{50}** value of 12.9 μM. iHCK-37 is used for chronic myeloid leukemia (CML) research.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

KB SRC 4

Cat. No.: HY-108488

KB SRC 4 is a potent, and highly selective **c-Src** inhibitor, with a **K_i** of 44 nM and a **K_d** of 86 nM, and shows no inhibition on c-Abl up to 125 μM; KB SRC 4 has antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KX1-004

Cat. No.: HY-18237

KX1-004 is a potent and non-ATP competitive **Src-PTK** inhibitor with an IC_{50} of 40 μM. KX1-004 protects the cochlea from hazardous noise and prevents noise-induced hearing loss (NIHL).



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lavendustin C

Cat. No.: HY-W013857

Lavendustin C is a potent Ca^{2+} **calmodulin-dependent kinase II (CaMK II)** inhibitor with an IC_{50} of 0.2 μM. Lavendustin C inhibits **EGFR**-associated tyrosine kinase (IC_{50}=0.012 μM) and **pp60**$^{c\text{-}src(+)}$ kinase (IC_{50}=0.5 μM) .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lck Inhibitor

Cat. No.: HY-12072

Lck Inhibitor is a potent, orally active **Lck (lymphocyte specific kinase)** inhibitor with IC_{50}s of 7, 2.1, 4.2 and 200 nM for Lck, Lyn, Src and Syk kinases, respectively. Lck Inhibitor shows >1000-fold selectivity for Lck over MAPK, CDK and RSK family representatives.



Purity: 98.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lck inhibitor 2

Cat. No.: HY-10644

Lck inhibitor 2 is a bis-anilinopyrimidine inhibitor of tyrosine kinases including LCK, BTK, LYN, SYK, and TXK. The IC50 values are 13nM, 9nM, 3nM, 26nM and 2nM for Lck, Btk, Lyn, Btk and Txk respectively.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lck-IN-1

Cat. No.: HY-138202

Lck-IN-1 is a potent lymphocyte protein tyrosine kinase **(Lck)** inhibitor extracted from patent WO2007013673A1, example 48.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lyn peptide inhibitor

Cat. No.: HY-P1111

Lyn peptide inhibitor is a potent and cell-permeable inhibitor of **Lyn-coupled IL-5 receptor** signaling pathway, while keeping other signals intact.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lyn peptide inhibitor TFA

Cat. No.: HY-P1111A

Lyn peptide inhibitor TFA is a potent and cell-permeable inhibitor of **Lyn-coupled IL-5 receptor** signaling pathway, while keeping other signals intact.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Masitinib

(AB1010)

Cat. No.: HY-10209

Masitinib (AB1010) is a potent, orally bioavailable, and selective inhibitor of **c-Kit** (IC_{50}=200 nM for human recombinant c-Kit). It also inhibits **PDGFRα/β** (IC_{50}s=540/800 nM), **Lyn** (IC_{50}= 510 nM for LynB), **Lck**, and, to a lesser extent, **FGFR3** and **FAK**.



Purity: 99.98%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Masitinib mesylate

(AB-1010 mesylate)

Cat. No.: HY-10209A

Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of **c-Kit** (IC_{50}=200 nM for human recombinant c-Kit). It also inhibits **PDGFRα/β** (IC_{50}s=540/800 nM), **Lyn** (IC_{50}= 510 nM for LynB), **Lck**, and, to a lesser extent, **FGFR3** and **FAK**.



Purity: 99.76%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

MNS

(NSC 170724; 5-(2-Nitrovinyl)benzodioxole)

Cat. No.: HY-78263

MNS (NSC 170724), the beta-nitrostyrene derivative, is a potent **tyrosine kinase** inhibitor and a broad-spectrum antiplatelet agent.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Multi-kinase-IN-1

Cat. No.: HY-146014

Multi-kinase-IN-1 (Compound 11k) is a potent **kinase** inhibitor with antitumor activity.
Multi-kinase-IN-1 induces cell **apoptosis**, and can be studied for **colorectal cancer**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Osteogenic Growth Peptide (10-14)

(OGP(10-14); Historphin)

Cat. No.: HY-107024

Osteogenic Growth Peptide (10-14) (OGP(10-14)), the C-terminal truncated pentapeptide of osteogenic growth peptide (OGP), retains the full OGP-like activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

PD-089828

Cat. No.: HY-112345

PD-089828 is an ATP competitive inhibitor of **FGFR-1**, **PDGFR-β** and **EGFR** (IC_{50}s=0.15, 1.76, and 5.47 μM, respectively) and a noncompetitive inhibitor of **c-Src** tyrosine kinase (IC_{50}=0.18 μM). PD-089828 also inhibits **MAPK** with an IC_{50} of 7.1 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PD-161570

Cat. No.: HY-100434

PD-161570 is a potent and ATP-competitive **human FGF-1 receptor** inhibitor with an IC_{50} of 39.9 nM and a K_i of 42 nM. PD-161570 also inhibits the **PDGFR**, **EGFR** and **c-Src tyrosine kinases** with IC_{50} values of 310 nM, 240 nM, and 44 nM, respectively.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PD166326

Cat. No.: HY-118144

PD166326 is a pyridopyrimidine-type inhibitor of **receptor tyrosine kinases**, with IC_{50}s of 6 nM and 8 nM for **Src** and **Abl**, respectively. PD166326 exhibits antileukemic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PD173955

Cat. No.: HY-10395

PD173955 is src family-selective tyrosine kinase inhibitor with IC50 of ~22 nM for Src, Yes and Abl kinase; less potent for FGFRα and no activity on InsR and PKC.



Purity: 99.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

PD180970

Cat. No.: HY-103274

PD180970 is a highly potent and ATP-competitive **$p210^{Bcr-Abl}$ kinase** inhibitor, with an IC_{50} of 5 nM for inhibiting the autophosphorylation of **$p210^{Bcr-Abl}$**. PD180970 also inhibits **Src** and **KIT** kinase with IC_{50}s of 0.8 nM and 50 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Pelitinib

(EKB-569; WAY-EKB 569)

Cat. No.: HY-32718

Pelitinib (EKB-569;WAY-EKB 569) is an irreversible inhibitor of **EGFR** with an IC_{50} of 38.5 nM; also slightly inhibits Src, MEK/ERK and ErbB2 with IC_{50}s of 282, 800, and 1255 nM, respectively.



Purity: 98.80%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Pelitinib-d6

Cat. No.: HY-32718S

Pelitinib-d6 (EKB-569-d6) is the deuterium labeled Pelitinib. Pelitinib (EKB-569) is an irreversible inhibitor of **EGFR** with an IC_{50} of 38.5 nM; also slightly inhibits Src, MEK/ERK and ErbB2 with IC_{50}s of 282, 800, and 1255 nM, respectively.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

PF 477736

(PF 00477736)

Cat. No.: HY-10032

PF 477736 (PF 00477736) is a potent, selective and ATP-competitive inhibitor of **Chk1**, with a K_i of 0.49 nM, it is also a **Chk2** inhibitor, with a K_i of 47 nM.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Ponatinib

(AP24534) Cat. No.: HY-12047

Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC_{50}s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for **Abl**, **PDGFRα**, **VEGFR2**, **FGFR1**, and **Src**, respectively.



Purity: 99.43%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Ponatinib hydrochloride

(AP24534 hydrochloride) Cat. No.: HY-108766

Ponatinib (AP24534) hydrochloride is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC_{50}s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for **Abl**, **PDGFRα**, **VEGFR2**, **FGFR1**, and **Src**, respectively.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Ponatinib-d8

(AP24534-d8) Cat. No.: HY-12047S

Ponatinib D8 (AP24534 D8) is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC_{50}s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for **Abl**, **PDGFRα**, **VEGFR2**, **FGFR1**, and **Src**, respectively.



Purity: 98.44%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PP1

(AGL 1872; EI 275) Cat. No.: HY-13804

PP1 is a potent, and **Src** family-selective tyrosine kinase inhibitor with IC_{50} of 5 and 6 nM for Lck and Fyn, respectively.



Purity: 98.62%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

PP121

Cat. No.: HY-10372

PP121 is a multi-targeted kinase inhibitor with IC_{50}s of 10, 60, 12, 14, 2 nM for **mTOR**, **DNK-PK**, **VEGFR2**, **Src**, **PDGFR**, respectively.



Purity: 99.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

PP2

(AGL 1879) Cat. No.: HY-13805

PP2 is a reversible and ATP-competitive **Src** family kinases inhibitor with IC_{50}s of 4 and 5 nM for **Lck** and **Fyn**, respectively.



Purity: 98.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PP58

Cat. No.: HY-18622

PP58 is a pyrido[2,3-d]pyrimidine-based compound that inhibits **PDGFR**, **FGFR** and **Src** family activities with nanomolar IC_{50} values.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

Rebastinib

(DCC-2036) Cat. No.: HY-13024

Rebastinib (DCC-2036) is an orally active, non-ATP-competitive **Bcr-Abl** inhibitor for $Abl1^{WT}$ and $Abl1^{T315I}$ with IC_{50}s of 0.8 nM and 4 nM, respectively. Rebastinib also inhibits SRC, KDR, FLT3, and Tie-2, and has low activity to seen towards c-Kit.



Purity: 99.91%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

RK-24466

(KIN 001-51) Cat. No.: HY-108318

RK-24466 (KIN 001-51) is a potent and selective **Lck** inhibitor; inhibits Lck (64-509) and LckCD isoforms with IC_{50}s of less than 1 and 2 nM, respectively.



Purity: 98.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Saracatinib

(AZD0530) Cat. No.: HY-10234

Saracatinib (AZD0530) is a potent **Src** family inhibitor with IC_{50}s of 2.7 to 11 nM for **c-Src**, **Lck**, **c-YES**, **Lyn**, **Fyn**, **Fgr**, and **Blk**. Saracatinib shows high selectivity over other tyrosine kinases.



Purity: 99.97%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Scutellarein

(6-Hydroxyapigenin; 4',5,6,7-Tetrahydroxyflavone) Cat. No.: HY-N0752

Scutellarin, a main active ingredient extracted from Erigeron breviscapus (Vant.) Hand-Mazz., has been wildly used to treat acute cerebral infarction and paralysis induced by cerebrovascular diseases.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

Secretin, canine

Cat. No.: HY-P1784

Secretin, canine is an endocrine hormone that stimulates the secretion of bicarbonate-rich pancreatic fluids. Secretin, canine can regulates gastric chief cell function and paracellular permeability in canine gastric monolayers by a Src kinase-dependent pathway.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SM1-71

Cat. No.: HY-136848

SM1-71 (compound 5) is a potent **TAK1** inhibitor, with a K_i of 160 nM, it also can covalently inhibit **MKNK2**, **MAP2K1/2/3/4/6/7**, **GAK**, **AAK1**, **BMP2K**, **MAP3K7**, **MAPKAPK5**, **GSK3A/B**, **MAPK1/3**, **SRC**, **YES1**, **FGFR1**, **ZAK (MLTK)**, **MAP3K1**, **LIMK1** and **RSK2**.



Purity: 96.00%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Squarunkin A hydrochloride

Cat. No.: HY-127002A

Squarunkin A hydrochloride is a potent and selective **UNC119-cargo interaction** inhibitor (IC_{50} of 10 nM for inhibiting the **UNC119A-myristoylated Src N-terminal peptide interaction**). Squarunkin A hydrochloride interferes with the activation of **Src kinase** in cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Src Inhibitor 1

(Src Kinase Inhibitor 1; Src-I1) Cat. No.: HY-101053

Src Inhibitor 1 is a potent, ATP-competitive and selective dual site **Src** tyrosine kinase inhibitor with IC_{50} values of 44 nM for Src and 88nM for Lck.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

Src Inhibitor 3

Cat. No.: HY-130254

Src Inhibitor 3 is a potent, orally active **c-terminal Src kinase (CSK)** with IC_{50} values below 3 nM and 4 nM in CSK HTRF and Caliper assay, respectively. Src Inhibitor 3 shows the ability to increase T cell proliferation induced by T cell receptor signaling.



Purity: 98.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SU6656

Cat. No.: HY-B0789

SU6656 is a **Src family kinases** inhibitor with IC_{50}s of 280, 20, 130, 170 nM for Src, Yes, Lyn, and Fyn, respectively. SU6656 inhibits FAK phosphorylation at Y576/577, Y925, Y861 sites. SU6656 also inhibits p-AKT.



Purity: 96.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

T338C Src-IN-1

Cat. No.: HY-16905

T338C Src-IN-1 is a potent mutant-Src T338C inhibitor; exhibited the most potent inhibition of T338C(IC50=111 nM) relative to WT c-Src (10-fold increase).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

T338C Src-IN-2

Cat. No.: HY-16906

T338C Src-IN-2 is a potent mutant c-Src T338C kinase inhibitor with IC50 of 317 nM; also inhibits T338C/V323A and T338C/V323S with IC50 of 57 nM/19 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TG 100572

Cat. No.: HY-10184

TG 100572 is a multi-targeted kinase inhibitor which inhibits **receptor tyrosine kinases** and **Src kinases**; has IC_{50}s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TG 100572 Hydrochloride

Cat. No.: HY-10185

TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits **receptor tyrosine kinases** and **Src kinases**; has IC_{50}s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

TG 100801

Cat. No.: HY-10186

TG 100801 is a prodrug that generates TG 100572 by de-esterification in development to treat age-related macular degeneration.



Purity: 98.60%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg

TG 100801 Hydrochloride

Cat. No.: HY-10187

TG 100801 Hydrochloride is a prodrug that generates TG 100572 by de-esterification in development to treat age-related macular degeneration.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Tirbanibulin

(KX2-391; KX-01)

Cat. No.: HY-10340

Tirbanibulin (KX2-391) is an inhibitor of **Src** that targets the peptide substrate site of Src, with GI_{50} of 9-60 nM in cancer cell lines.



Purity: 99.33%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tirbanibulin dihydrochloride

(KX2-391 dihydrochloride; KX-01 dihydrochloride)

Cat. No.: HY-10340A

Tirbanibulin (dihydrochloride) (KX2-391 (dihydrochloride)) is an inhibitor of **Src** that targets the peptide substrate site of Src, with GI_{50} of 9-60 nM in cancer cell lines.



Purity: 96.24%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tirbanibulin Mesylate

(KX2-391 Mesylate; KX01 Mesylate)

Cat. No.: HY-10340B

Tirbanibulin Mesylate (KX2-391 Mesylate) is an inhibitor of **Src** that targets the peptide substrate site of Src, with GI_{50} of 9-60 nM in cancer cell lines.



Purity: 99.97%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TL02-59

Cat. No.: HY-112852

TL02-59 is an orally active, selective Src-family kinase **Fgr** inhibitor with an IC_{50} of 0.03 nM. TL02-59 inhibits **Lyn** and **Hck** with IC_{50}s of 0.1 nM and 160 nM, respectively. TL02-59 potently suppresses acute myelogenous leukemia (AML) cell growth.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TL02-59 dihydrochloride

Cat. No.: HY-112852A

TL02-59 dihydrochloride is an orally active, selective Src-family kinase **Fgr** inhibitor with an IC_{50} of 0.03 nM. TL02-59 dihydrochloride inhibits **Lyn** and **Hck** with IC_{50}s of 0.1 nM and 160 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tolimidone

(MLR-1023)

Cat. No.: HY-59047

Tolimidone is a potent and selective allosteric activator of **Lyn kinase** with an EC_{50} of 63 nM.



Purity: 99.98%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg

Tyrosine Kinase Peptide 1

Cat. No.: HY-P2547

Tyrosine Kinase Peptide 1 is a control substrate peptide for c-Src assay.

KVEKIGEGTYGVVYK

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

UM-164

(DAS-DFGO-II)

Cat. No.: HY-112182

UM-164 (DAS-DFGO-II) is a highly potent inhibitor of **c-Src** with a K_d of 2.7 nM. UM-164 also potently inhibits **p38α** and **p38β**.



Purity: 98.91%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

WH-4-023

(Dual LCK/SRC inhibitor)

Cat. No.: HY-12299

WH-4-023 is a potent and selective dual **Lck/Src** inhibitor with IC_{50} of 2 nM/6 nM for Lck and Src kinase respectively; little inhibition on p38α and KDR.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

XL228

Cat. No.: HY-15749

XL228 is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 5, 3.1, 1.6, 6.1, 2 nM for **Bcr-Abl**, **Aurora A**, **IGF-1R**, **Src** and **Lyn**, respectively.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

YH-306

Cat. No.: HY-120213

YH-306 is an antitumor agent. YH-306 suppresses colorectal tumour growth and metastasis via **FAK** pathway. YH-306 significantly inhibits the migration and invasion of colorectal cancer cells. YH-306 potently suppresses uninhibited proliferation and induces cell **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

β-Hydroxyisovalerylshikonin

Cat. No.: HY-N4201

Beta-hydroxyisovalerylshikonin is a natural product isolated from Lithospermium radix, acts as a potent inhibitor of **protein tyrosine kinases (PTK)**, with IC_{50}s of 0.7μM and 1μM for EGFR and v-Src receptor, respectively.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg